Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting

Zentalis Pharmaceuticals ( (ZNTL) ) has provided an update.

On June 17, 2025, Zentalis Pharmaceuticals held its 2025 Annual Meeting of Stockholders, where 80.9% of the company’s outstanding common stock was represented. During the meeting, Scott Myers, Karan Takhar, and Luke Walker, M.D., were elected as Class II Directors, and the appointment of Ernst & Young LLP as the independent public accounting firm was ratified, along with the approval of executive compensation.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development of small molecule therapeutics for the treatment of cancer.

Average Trading Volume: 840,040

Technical Sentiment Signal: Sell

Current Market Cap: $108.6M

See more data about ZNTL stock on TipRanks’ Stock Analysis page.